CA-SIRIUS-THERAPEUTICS
Sirius Therapeutics, announced it has dosed the first subject in a Phase 1, first-in-human clinical trial in Australia of SRSD107 on January 30th 2024, its next generation siRNA therapeutic targeting coagulation Factor XI (FXI), for the prevention and treatment of thromboembolic disorders. SRSD107 is the second clinical candidate in the company’s portfolio of next generation siRNA therapeutics to treat cardiovascular diseases. The company recently began clinical trials of SRSD101 in China for the treatment of dyslipidemia following IND clearance from the China National Medical Products Administration.
“This trial is based on in vivo studies that demonstrated a nearly 100% reduction of FXI levels for up to 6 months, without bleeding events, after a single subcutaneous dose,” said Dr. Qunsheng Ji, Sirius Therapeutics’ Chief Executive Officer. “The trial will provide an opportunity to evaluate SRSD107’s potential as a differentiated therapeutic for these common disorders globally.”
The SRSD107 Phase 1 study, which is being conducted in healthy volunteers in Australia, will evaluate SRSD107’s safety, tolerability, pharmacokinetics, and pharmacodynamics at single ascending doses and multiple ascending doses.
About Thromboembolic Disorders
Thrombosis, or blood clot formation, is the common underlying mechanism of most cases of myocardial infarction, ischemic stroke, and venous thromboembolism. According to a study in The Lancet of regional and global mortality, thromboembolic disorders are estimated to cause 1 in 4 deaths worldwide1.
About SRSD107
SRSD107 is a novel double-stranded small interfering ribonucleic acid (siRNA). Developed by Sirius Therapeutics, SRSD107 specifically targets coagulation factor XI (FXI) mRNA and inhibits FXI protein expression, thereby blocking the intrinsic coagulation pathway and promoting anticoagulant/anti-thrombotic effects. SRSD107 has been engineered for the potential to enable once or twice-a-year dosing.
About Sirius Therapeutics
Sirius is an innovative, clinical stage biotech company developing next generation siRNA therapy for global markets. We are dedicated to discovering and developing new treatment options for cardiovascular disease patients. Our most advanced products are SRSD107 for the treatment of thromboembolic disorders, and SRSD101 for the treatment of dyslipidemia. Founded in 2021 by a world-class leadership team and investors, Sirius has established an innovative discovery center in the United States and translational medicine center in China. Sirius has raised nearly US$100 million funding to date from OrbiMed, Creacion Ventures, Hankang Capital, Delos Capital, and the leadership team.
[1] Lozano R, Naghavi M, Foreman K, et al. Lancet. 2012;380, 2095-1128.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240201912539/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
EsriIntroduces Latest ArcGIS Integrations for Microsoft Fabric18.11.2025 23:05:00 CET | Press release
Users Can Now Access a Powerful Combination of Spatial Analytics and Intelligent Mapping Esri, the global leader in location intelligence, today announced General Availability of ArcGIS GeoAnalytics for Microsoft Fabric. Also now in public preview is ArcGIS Maps for Microsoft Fabric, a mapping tool enabling users to easily add context with business, lifestyle, demographic, and environmental data to enrich enterprise data in Microsoft OneLake. “This integration makes some of Esri’s core capabilities accessible for data professionals directly from their Microsoft Fabric environment,” said Jack Dangermond, Esri president. “We are pleased to advance our long-standing strategic collaboration with Microsoft to help our shared customers unlock spatial insights and reveal unexplored patterns.” There has been growing market demand among data scientists, data engineers, business analysts, and their executive stakeholders for spatial analytics and mapping. Esri’s GeoAnalytics for Fabric will allo
Andersen Consulting indgår samarbejdsaftale med Business Meets Culture18.11.2025 22:18:00 CET | Pressemeddelelse
Andersen Consulting udvider sin globale rækkevidde gennem en samarbejdsaftale med Business Meets Culture (BMC), der er en global strategikonsulentvirksomhed med lokationer i Latinamerika, Europa og USA. Med afsæt i kulturel intelligens og indsigt i menneskelig adfærd specialiserer BMC sig i strategi, brandstrategi, kommerciel planlægning, innovation og altid transformation. Med deres egne metoder og tværfaglige teams hjælper BMC virksomheder med at knytte strategi tættere til mennesker ved at omsætte udvikling, adfærd og forretningsmæssige udfordringer til relevante muligheder for vækst. Virksomheden samarbejder med førende aktører på tværs af brancher som forbrugsvarer, finansielle tjenester, telekommunikation og teknologi. "Samarbejdet med Andersen Consulting giver os mulighed for at styrke rækkevidden og effekten af vores kulturelt forankrede strategiske arbejde," siger Fernando Parodi, som er CEO for BMC. "Sammen står vi endnu stærkere og kan tilbyde organisationer skarpere perspek
Finalists Announced for 2026 SPIE Startup Challenge, Showcasing Innovative, Investment-Ready Optics and Photonics Technologies and Applications18.11.2025 22:05:00 CET | Press release
The annual pitch competition final will be held at SPIE Photonics West Sevenearly-stage startup companies have been selected to compete for a top prize of $10,000 at the 16th annual SPIE Startup Challenge at Photonics West on 20 January. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251118106028/en/ Eventual winner, Trey Daunis of Max-IR Labs, pitches their innovative technology during the 2025 SPIE Startup Challenge, engaging judges and a packed audience at SPIE Photonics West. The SPIE Startup Challenge is a competitive entrepreneurial platform for new businesses that utilize optics and photonics for innovative products or applications. Participating teams are competing for sponsored prizes, in addition to gaining increased visibility with potential investors and exposure to potential collaborators or partners. Cash prizes of $10,000, $5,000, and $2,500, provided by Startup Challenge Founding Partner Jenoptik, will be awa
Owkin Unveils Europe’s First Pan-European Agentic Infrastructure for Biology at the Franco-German Digital Sovereignty Summit18.11.2025 21:48:00 CET | Press release
At today’s Franco-German Summit on Digital Sovereignty in Berlin, Owkin, together with leading academic partners Gustave Roussy (France) and Charité Comprehensive Cancer Center (Germany), announced a landmark initiative to build the first pan-European agentic infrastructure to make biological data AI-ready, as a key step towards biological super intelligence. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251118529021/en/ Thomas Clozel (CEO of Owkin) joins Emmanuel Macron, Friedrich Merz and others at the Franco-German Digital Sovereignty Summit The project aims to develop and deploy modern AI methods to support biological research and drug development. An initial focus will be on supporting the harmonization and structuring of biomedical data across Europe to enhance scientific collaboration. It will combine agentic AI systems and cutting-edge biomedical data structuring, to power a new reasoning model capable of automating
Reply at Microsoft Ignite 2025: Showcasing AI Innovation, Copilot Experiences, and Intelligent Enterprise Solutions18.11.2025 21:30:00 CET | Press release
Reply [EXM, STAR: REY] is taking part in Microsoft Ignite 2025, a premier event for technology professionals and decision-makers hosted by Microsoft, held from November 18 to 21 in San Francisco, California. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251118836834/en/ A trusted Microsoft partner since 1996, Reply empowers organizations to innovate with Microsoft technologies, driving agility, intelligence, and sustainable growth. A trusted Microsoft partner since 1996, Reply empowers organizations to innovate with Microsoft technologies, driving agility, intelligence, and sustainable growth. With more than 2,000 Microsoft certifications across its network of companies – including Business Elements Reply, Cluster Reply, Solidsoft Reply, Light Reply, Root16 Reply, Valorem Reply, WM Reply and Zest Reply – the group has achieved all six Microsoft Solutions Partner designations. This year, Reply is also celebrating two major h
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom